Pulmonary Histoplasmosis

Tobón, Ángela M.; Gómez, Beatriz L.

doi:10.1007/s11046-021-00588-4

Cited by 37 publications

(33 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…HIV-infected individuals are at greatly increased risk of developing histoplasmosis, especially those with CD4 + T-cell counts <200 cells/μl ( 121 ). Histoplasma capsulatum yeasts can infect macrophages and survive within phagocytic cells ( 122 ).…”

Section: Common Fungal Diseases In Hiv Infectionmentioning

confidence: 99%

Neglected mycobiome in HIV infection: Alterations, common fungal diseases and antifungal immunity

Yang

Moog

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Human immunodeficiency virus (HIV) infection might have effects on both the human bacteriome and mycobiome. Although many studies have focused on alteration of the bacteriome in HIV infection, only a handful of studies have also characterized the composition of the mycobiome in HIV-infected individuals. Studies have shown that compromised immunity in HIV infection might contribute to the development of opportunistic fungal infections. Despite effective antiretroviral therapy (ART), opportunistic fungal infections continue to be a major cause of HIV-related mortality. Human immune responses are known to play a critical role in controlling fungal infections. However, the effect of HIV infection on innate and adaptive antifungal immunity remains unclear. Here, we review recent advances in understanding of the fungal microbiota composition and common fungal diseases in the setting of HIV. Moreover, we discuss innate and adaptive antifungal immunity in HIV infection.

show abstract

Section: Common Fungal Diseases In Hiv Infectionmentioning

confidence: 99%

Neglected mycobiome in HIV infection: Alterations, common fungal diseases and antifungal immunity

Yang

Moog

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Enquanto o tratamento conservador é adotado em pacientes imunocompetentes assintomáticos, terapia antifúngica específica deve ser oferecida em pacientes sintomáticos com lesões infiltrativas difusas. (9) O tratamento de escolha é itraconazol oral (200 mg/dia) por seis a doze semanas. (10) Em conclusão, acreditamos que a histoplasmose endobrônquica deve ser considerada parte do diagnóstico diferencial de lesões endobrônquicas em pacientes jovens, mesmo em áreas não endêmicas.…”

Section: Ao Editorunclassified

Endobronchial histoplasmosis mimicking primary bronchogenic carcinoma during the COVID-19 pandemic

et al. 2022

View full text Add to dashboard Cite

“…In addition to the host immune status, the exposure to a variable amount of the inoculum can influence the progress of the disease [ 10 ]. Furthermore, there is also the possibility of developing a latency phase (chronic phase), in which H. capsulatum behaves as an opportunistic pathogen and can cause infection if the host presents a decrease in immunity [ 20 , 21 , 22 , 23 ].…”

Section: Introductionmentioning

confidence: 99%

Comparative Genomics of Histoplasma capsulatum and Prediction of New Vaccines and Drug Targets

Almeida

Roque

Felice

et al. 2023

JoF

View full text Add to dashboard Cite

Histoplasma capsulatum is a thermodymorphic fungus that causes histoplasmosis, a systemic mycosis that presents different clinical manifestations, ranging from self-limiting to acute lung infection, chronic lung infection and disseminated infection. Usually, it affects severely immunocompromised patients although immunocompetent patients can also be infected. Currently, there are no vaccines to prevent histoplasmosis and the available antifungal treatment presents moderate to high toxicity. Additionally, there are few options of antifungal drugs. Thus, the aim of this study was to predict possible protein targets for the construction of potential vaccine candidates and predict potential drug targets against H. capsulatum. Whole genome sequences from four previously published H. capsulatum strains were analyzed and submitted to different bioinformatic approaches such as reverse vaccinology and subtractive genomics. A total of four proteins were characterized as good protein candidates (vaccine antigens) for vaccine development, three of which are membrane-bound and one is secreted. In addition, it was possible to predict four cytoplasmic proteins which were classified as good protein candidates and, through molecular docking performed for each identified target, we found four natural compounds that showed favorable interactions with our target proteins. Our study can help in the development of potential vaccines and new drugs that can change the current scenario of the treatment and prevention of histoplasmosis.

show abstract

Pulmonary Histoplasmosis

Cited by 37 publications

References 46 publications

Neglected mycobiome in HIV infection: Alterations, common fungal diseases and antifungal immunity

Neglected mycobiome in HIV infection: Alterations, common fungal diseases and antifungal immunity

Endobronchial histoplasmosis mimicking primary bronchogenic carcinoma during the COVID-19 pandemic

Comparative Genomics of Histoplasma capsulatum and Prediction of New Vaccines and Drug Targets

Contact Info

Product

Resources

About